Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $468.42 +0.35%
Revenue Growth %: +8.4%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
CRWS, MEI, PODC, More
Revenue Growth %: +8.4%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
CRWS, MEI, PODC, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $426 million versus the consensus estimate of $427.94 million.
Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- MSCI acquires First Street for $120M to expand climate risk data
- Stifel Canada Starts BlackBerry (BB) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
